NCT02541942 - Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2015

Primary Completion Date

April 15, 2016

Study Completion Date

April 15, 2016

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

OTHER

No treatment given

For patient convenience, genetic material will be collected in the form of saliva samples.

Trial Locations (15)

Novo Nordisk Investigational Site, Bangkok

Novo Nordisk Investigational Site, Belgrade

Novo Nordisk Investigational Site, Novi Sad

Novo Nordisk Investigational Site, Atlanta

Novo Nordisk Investigational Site, Tampa

Novo Nordisk Investigational Site, Kuala Lumpur

Novo Nordisk Investigational Site, Iowa City

Novo Nordisk Investigational Site, Timișoara

Novo Nordisk Investigational Site, Tucson

Novo Nordisk Investigational Site, Boston

Novo Nordisk Investigational Site, Athens

Novo Nordisk Investigational Site, Thessaloniki

Novo Nordisk Investigational Site, Kashihara-shi, Nara

Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo

Novo Nordisk Investigational Site, Suginami-ku, Tokyo